Moderna's Omicron Booster Works Against New Variants, Company Says
TimeAPR 3 2023
Granted, the first vaccines produced for COVID weren't the perfect long-term solution, but it's important to remain agile to fine-tune current vaccines for a rapidly-evolving virus. When we add more options to the toolkit, personal and collective decision-making processes also improve — this is vital in the fight against variants.
Current COVID vaccines and boosters don't prevent people from becoming infected and don't fully stop long-COVID — these jabs were designed to reduce the disease severity and hospitalization. Perhaps it's time to focus fully on a "v2.0" vaccine to protect against all variants, block transmission, and prevent long-COVID. This upgrade, instead of tweaking what we have now, would go a long way in helping people to calculate their own risk.
While Moderna — along with Pfizer and other drug companies — should be commended for the speed and efficiency with which they initially developed vaccines against COVID, they've also acted as shameless profiteers, taking advantage of the crisis to rake in absurd profits. Their endless development of boosters is just a small part of this. More must be done to limit their excessive gains that come at great public expense.